OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Rosenthal on Treatment Strategies for Indolent Lymphomas

October 20th 2016

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses some of the treatment strategies for patients with indolent lymphomas.

Dr. El-Khoueiry on Evolving Role of Immunotherapy in HCC

October 19th 2016

Anthony B. El-Khoueiry, MD, associate professor of Clinical Medicine, USC Norris Comprehensive Cancer Center, discusses the role that immunotherapy currently plays, and will continue to play, in the treatment landscape of hepatocellular carcinoma (HCC).

Stefani Spranger on What Every Oncologist Should Know About Immunotherapy

October 19th 2016

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses the basic knowledge all oncologists should have regarding immunotherapy.

Dr. Rimm on Biomarker Testing in Lung Cancer

October 19th 2016

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses various options for biomarker testing in lung cancer.

Dr. Mikhail Fedyanin on Mutation Discordance in CRC

October 19th 2016

Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses mutation discordance in the primary tumor and metastases in patients with colorectal cancer (CRC).

Dr. Blackwell on Treatment Landscape of HER2+ Breast Cancer

October 19th 2016

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the available treatments for patients with HER2-positive breast cancer, as well as other agents that are in development.

Dr. McGuire on Evolving Role of Surgery in Metastatic Breast Cancer

October 19th 2016

Kandace McGuire, MD, associate professor of Surgery, UNC Department of Surgery, Division of Surgical Oncology, UNC School of Medicine, discusses the evolving role of surgery in the treatment of patients with metastatic breast cancer.

Dr. Shaji Kumar on New Criteria for Response and MRD Assessment in Multiple Myeloma

October 19th 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the International Myeloma Working Group’s recently released updated consensus criteria for response and minimal residual disease (MRD) assessment in multiple myeloma.

Bridgett Harr on Managing Long-term Side Effects in Head and Neck Cancer

October 19th 2016

Bridgett Harr, CNP, radiation oncology, Cleveland Clinic, discusses survivorship and managing long-term side effects in head and neck cancer.

Sangeetha Palakurthi on FDA Approval of Atezolizumab in NSCLC

October 19th 2016

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses the FDA approval of atezolizumab (Tecentriq) for the treatment of patients with non–small cell lung cancer (NSCLC).

Dr. Sanft on Treatment Options in HER2-Positive Breast Cancer

October 18th 2016

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discusses standard treatment options for patients with HER2-positive breast cancer.

Dr. Pietrantonio on the Design and Rationale Behind a Nomogram to Predict Survival Rates in CRC

October 18th 2016

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses a nomogram that can predict 12-week survival rates for patients with colorectal cancer.

Dr. Jasgit Sachdev on Antibody-Drug Conjugate PF-06647020 in Ovarian Cancer

October 18th 2016

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a phase I study of PF-06647020, an antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in patients with platinum-resistant ovarian cancer.

Dr. Albiges on Immunotherapy in Renal Cell Carcinoma

October 18th 2016

Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses how immunotherapy has had an impact on the field of renal cell carcinoma (RCC).

Dr. Hortobagyi on MONALEESA-2 Trial Results in HR+ Breast Cancer

October 18th 2016

Gabriel N. Hortobagyi, MD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses findings from the phase III MONALEESA-2 trial, which looked at the addition of the CDK 4/6 inhibitor ribociclib to endocrine therapy in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.

Dr. Jean-Yves Blay on Eribulin in Leiomyosarcoma

October 18th 2016

Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.

Dr. Somlo on Novel Agents in Multiple Myeloma

October 18th 2016

George Somlo, MD, medical oncologist, City of Hope, discusses some of the novel agents being evaluated for the treatment of patients with multiple myeloma.

Dr. Iyengar on the Rationale Behind Hypofractionated Radiation in NSCLC

October 18th 2016

Puneeth Iyengar, MD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the rationale behind the use of hypofractionated radiation as a treatment for patients with non–small cell lung cancer.

Dr. Daniel Eidelberg Spratt on Risk Factors in Prostate Cancer

October 17th 2016

Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses challenges regarding the classification of risk groups in prostate cancer.

Dr. Jan A. Burger on Role of MRD-Negativity in CLL

October 15th 2016

Jan A. Burger, MD, PhD, associate professor, department of leukemia, division of cancer medicine, The University of Texas MD Anderson Cancer Center, discusses the role of minimal residual disease (MRD)-negativity in chronic lymphocytic leukemia (CLL).